Clinical Pharmacokinetics of Levetiracetam

左乙拉西坦 药代动力学 医学 分配量 摄入 肾功能 药理学 癫痫 口服 尿 生物利用度 不利影响 胃肠病学 内科学 精神科
作者
Philip N. Patsalos
出处
期刊:Clinical Pharmacokinectics [Adis, Springer Healthcare]
卷期号:43 (11): 707-724 被引量:455
标识
DOI:10.2165/00003088-200443110-00002
摘要

Since 1989, eight new antiepileptic drugs (AEDs) have been licensed for clinical use. Levetiracetam is the latest to be licensed and is used as adjunctive therapy for the treatment of adult patients with partial seizures with or without secondary generalisation that are refractory to other established first-line AEDs. Pharmacokinetic studies of levetiracetam have been conducted in healthy volunteers, in adults, children and elderly patients with epilepsy, and in patients with renal and hepatic impairment. After oral ingestion, levetiracetam is rapidly absorbed, with peak concentration occurring after 1.3 hours, and its bioavailability is >95%. Co-ingestion of food slows the rate but not the extent of absorption. Levetiracetam is not bound to plasma proteins and has a volume of distribution of 0.5-0.7 L/kg. Plasma concentrations increase in proportion to dose over the clinically relevant dose range (500-5000 mg) and there is no evidence of accumulation during multiple administration. Steady-state blood concentrations are achieved within 24-48 hours. The elimination half-life in adult volunteers, adults with epilepsy, children with epilepsy and elderly volunteers is 6-8, 6-8, 5-7 and 10-11 hours, respectively. Approximately 34% of a levetiracetam dose is metabolised and 66% is excreted in urine unmetabolised; however, the metabolism is not hepatic but occurs primarily in blood by hydrolysis. Autoinduction is not a feature. As clearance is renal in nature it is directly dependent on creatinine clearance. Consequently, dosage adjustments are necessary for patients with moderate to severe renal impairment. To date, no clinically relevant pharmacokinetic interactions between AEDs and levetiracetam have been identified. Similarly, levetiracetam does not interact with digoxin, warfarin and the low-dose contraceptive pill; however, adverse pharmacodynamic interactions with carbamazepine and topiramate have been demonstrated. Overall, the pharmacokinetic characteristics of levetiracetam are highly favourable and make its clinical use simple and straightforward.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1234完成签到,获得积分10
1秒前
1秒前
1秒前
Tong完成签到,获得积分10
2秒前
jiaminzhao完成签到,获得积分10
3秒前
思源的应助被大方的妙梦采纳,获得10
3秒前
3秒前
4秒前
5秒前
落叶发布了新的文献求助10
5秒前
YM发布了新的文献求助10
6秒前
mumu完成签到 ,获得积分10
6秒前
6秒前
Frank发布了新的文献求助10
7秒前
San发布了新的文献求助10
7秒前
英吉利25发布了新的文献求助10
9秒前
仁爱嫣完成签到,获得积分10
9秒前
嘞嘞累哦完成签到,获得积分10
10秒前
ding的应助被陈鸿超采纳,获得10
10秒前
ZRH发布了新的文献求助10
10秒前
jerry完成签到 ,获得积分10
11秒前
斤斤计较发布了新的文献求助10
12秒前
12秒前
12秒前
12秒前
Qingzhu完成签到,获得积分10
14秒前
何糖完成签到 ,获得积分10
14秒前
Maestro_S的应助被感动的樱桃采纳,获得10
14秒前
syvshc的应助被QINYUYU采纳,获得10
16秒前
FashionBoy的应助被likes采纳,获得10
16秒前
16秒前
研友_VZG7GZ的应助被yun采纳,获得30
17秒前
李小晴天完成签到,获得积分10
17秒前
17秒前
可爱玫瑰发布了新的文献求助10
18秒前
19秒前
CodeCraft的应助被dengdeng采纳,获得10
19秒前
Yebo完成签到 ,获得积分10
19秒前
希尔巴德发布了新的文献求助10
19秒前
苹果紫完成签到 ,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192871
求助须知:如何正确求助?哪些是违规求助? 9579281
关于积分的说明 21864358
捐赠科研通 7792445
什么是DOI,文献DOI怎么找? 3437059
关于科研通互助平台的介绍 2560639
邀请新用户注册赠送积分活动 2483928